1374208-44-2

Usage

Uses

Used in Pharmaceutical Research and Development:
2,4-dichloro-6-fluoro-7-bromoquinazoline is used as a lead compound in the discovery and design of new anticancer agents. Its unique structural properties and promising biological activities make it a valuable tool for researchers in the field of oncology.
Used in Targeted Drug Delivery:
2,4-dichloro-6-fluoro-7-bromoquinazoline's structural properties allow for the development of targeted drug delivery systems, which can improve the efficacy and safety of cancer treatments. By incorporating 2,4-dichloro-6-fluoro-7-bromoquinazoline into these systems, researchers can potentially enhance the delivery of therapeutic agents to cancer cells while minimizing damage to healthy cells.
Used in Anticancer Drug Development:
2,4-dichloro-6-fluoro-7-bromoquinazoline exhibits promising biological activities that make it a potential candidate for the development of new anticancer drugs. Further research is needed to fully understand its pharmacological properties and potential applications in the treatment of various types of cancer.

Upstream product

• 1395493-30-7 2-amino-4-bromo-5-fluorobenzoic acid methyl ester 
• 1020717-99-0 4-bromo-5-fluoro-2-nitrobenzoic acid 
• 656-64-4 3-bromo-4-fluoroaniline 
• 1374208-43-1 7-bromo-6-fluoro-1H-quinazoline-2,4-dione 
• 1374208-42-0 3-fluoro-4-bromo-6-aminobenzoic acid 
• 1374208-41-9 5-fluoro-6-bromo-1H-indolin-2,3-dione 
• 1374208-40-8 N-(3-bromo-4-fluorophenyl)-2-hydroxyiminoacetamide 

Relevant academic research and scientific papers

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER

The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

Spiro-substituted pyrimido-cyclic compound, and preparation method and medical application thereof

The invention discloses a spiro-substituted pyrimido-cyclic compound with selective inhibition effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound or a prodrug thereof; the spiro-substituted pyrimido-cyclic compound is represented by a formula (I), and the definition of each group or symbol in the formula is shown in the specification in detail.In addition, the invention also discloses a pharmaceutical composition containing the compound and an application of the compound in preparation of cancer drugs.

Substituted Amino-Pyrimidine Derivatives

The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.